Amerikanische Gesellschaft für Hirudotherapie

Research progress of natural active compounds on improving podocyte function to reduce proteinuria in diabetic kidney disease

Review published in Renal Failure (2023)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewGenomik & ProteomikSpeichel-PharmakologieGong L et al. · Renal failure, 2023

Abstract

Diabetic kidney disease (DKD) is a primary cause of end-stage renal disease. Proteinuria is a clinical indicator of the different stages of DKD, and podocyte injury is a major cause of proteinuria. Podocyte-specific proteins (PSPs) play important roles in the normal filtration of podocytes. Studies have shown that natural active compounds (NACs) can ameliorate proteinuria; however, the mechanism related to PSPs needs to be explored. In this study, the five stages of DKD related to proteinuria and the functions of PSPs are displayed separately. Mechanisms for ameliorating proteinuria and improving the PSPs of the 15 NACs are summarized. The in vitro and in vivo mechanistic research showed that five compounds, astragaloside IV, ligustrazine, berberine, emodin and resveratrol, exerted renal protective effects via AMPK signaling, icariin and berberine via TLR4 signaling, hirudin and baicalin via MAPK signaling, curcumin and baicalin via NF-κB signaling, and emodin via protein kinase RNA-like endoplasmic reticulum kinase signaling. The 13 PSPs were divided into five categories: actin cytoskeleton, basal domain, apical domain, slit diaphragm, and others. In conclusion, anti-inflammatory effects, anti-oxidative stress, and enhanced autophagy are the main mechanisms underlying the ameliorative effects of NACs. Podocyte apoptosis is mainly related to nephrin and podocin, which are the most studied slit diaphragm PSPs.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsHumansPodocytesDiabetic NephropathiesEmodinBerberineProteinuriaDiabetes Mellitus

Zusammenfassung

Reviews natural compounds improving podocyte function in diabetic kidney disease — includes detailed analysis of leech-hirudin's podocyte-protective effects.

Warum dies für die Hirudotherapie relevant ist

This review summarizes mechanisms by which natural active compounds (NACs) improve podocyte function and reduce proteinuria in diabetic kidney disease, listing hirudin among 15 NACs and identifying it as acting via MAPK signaling to exert renal protective effects. The abstract provides no information about the source of hirudin or any connection to leeches; hirudin appears solely as one compound in a broader pharmacological survey. The relevance to the leech secretome or hirudotherapy is therefore indirect and not stated by the authors. The abstract also does not report clinical efficacy data for any of the discussed compounds, including hirudin, for diabetic nephropathy.

Zitation

Research progress of natural active compounds on improving podocyte function to reduce proteinuria in diabetic kidney disease.

Gong L et al. · Renal failure, 2023

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.